ConductScience.org, home

Paper28652111

Cannabinoid Reduces Inflammatory Cytokines, Tumor Necrosis Factor-α, and Type I Interferons in Dermatomyositis In Vitro.

Robinson ES and 5 others. J Invest Dermatol, 2017. Cited by 36 papers, by iCite.

Cite this record

ConductScience Library. Cannabinoid Reduces Inflammatory Cytokines, Tumor Necrosis Factor-α, and Type I Interferons in Dermatomyositis In Vitro. Papers, record 28652111. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/28652111

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Cannabinoid Reduces Inflammatory Cytokines, Tumor Necrosis Factor-α, and Type I Interferons in Dermatomyositis In Vitro.
PubMed
Journal
J Invest Dermatol
PubMed
Year
2017
PubMed
Publication types
Journal Article, Research Support, N.I.H., Extramural, Research Support, U.S. Gov't, Non-P.H.S.
PubMed
Citations, by iCite
36
iCite
Relative citation ratio, by iCite
1.82
iCite
Revised in PubMed
2020-12-31
PubMed

Authors6

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Robinson ESElizabeth S
2Alves PPaul
3Bashir MMMuhammad M
4Zeidi MMajid
5Feng RRui
6Werth VPVictoria P

Source PubMed

Download CSV of authors

Topics12

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
CannabinoidsMajor topic
CytokinesMajor topic
DermatomyositisMajor topic
Interferon Type IMajor topic
Tumor Necrosis Factor-alphaMajor topic
Cohort Studies
Dronabinol
Humans
In Vitro Techniques
Prospective Studies
Sensitivity and Specificity
Severity of Illness Index

Source PubMed

Download CSV of topics

Grants2

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated bySource
I01 BX000706BLRD VAUnited StatesI01BX000706PubMed and NIHNIH RePORTER
R21 AR066286NIAMS NIH HHSUnited StatesR21AR066286PubMed and NIHNIH RePORTER

Download CSV of grants

References12

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
124856183Ultrapure ajulemic acid has improved CB2 selectivity with reduced CB1 activity.Bioorg Med Chem2014https://conductscience.org/library/papers/24856183PubMed
219124557Ajulemic acid, a synthetic cannabinoid, increases formation of the endogenous proresolving and anti-inflammatory eicosanoid, lipoxin A4.FASEB J2009https://conductscience.org/library/papers/19124557PubMed
38508790Cannabinoid-receptor expression in human leukocytes.Eur J Biochem1993https://conductscience.org/library/papers/8508790PubMed
47689702Molecular characterization of a peripheral receptor for cannabinoids.Nature1993https://conductscience.org/library/papers/7689702PubMed
518840450Ajulemic acid, a synthetic cannabinoid acid, induces an antiinflammatory profile of eicosanoids in human synovial cells.Life Sci2008https://conductscience.org/library/papers/18840450PubMed
612566094Suppression of human monocyte interleukin-1beta production by ajulemic acid, a nonpsychoactive cannabinoid.Biochem Pharmacol2003https://conductscience.org/library/papers/12566094PubMed
711037898TNFalpha-308A allele in juvenile dermatomyositis: association with increased production of tumor necrosis factor alpha, disease duration, and pathologic calcifications.Arthritis Rheum2000https://conductscience.org/library/papers/11037898PubMed
822217359Tumor necrosis factor α release in peripheral blood mononuclear cells of cutaneous lupus and dermatomyositis patients.Arthritis Res Ther2012https://conductscience.org/library/papers/22217359PubMed
922456539Gottron's papules exhibit dermal accumulation of CD44 variant 7 (CD44v7) and its binding partner osteopontin: a unique molecular signature.J Invest Dermatol2012https://conductscience.org/library/papers/22456539PubMed
1018040689Suppression of human macrophage interleukin-6 by a nonpsychoactive cannabinoid acid.Rheumatol Int2008https://conductscience.org/library/papers/18040689PubMed
1121398612Mechanism of endosomal TLR inhibition by antimalarial drugs and imidazoquinolines.J Immunol2011https://conductscience.org/library/papers/21398612PubMed
1212921755Ajulemic acid, a nonpsychoactive cannabinoid acid, induces apoptosis in human T lymphocytes.Clin Immunol2003https://conductscience.org/library/papers/12921755PubMed

Download CSV of references

Cited by22

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 36 citations.

PMIDTitleJournalYearIn PapersSource
42076122Cannabinoids for Dermatological Applications: Mechanistic Insights, Clinical Evidence, and Emerging Nanotechnology-Enabled Delivery Strategies.Pharmaceutics2026https://conductscience.org/library/papers/42076122PubMed
40285991CAR-T cell therapy in rheumatic diseases: a review article.Clin Rheumatol2026https://conductscience.org/library/papers/40285991PubMed
39841219Geraniol modulates inflammatory and antioxidant pathways to mitigate intestinal ischemia-reperfusion injury in male rats.Naunyn Schmiedebergs Arch Pharmacol2025https://conductscience.org/library/papers/39841219PubMed
39403556
Long-Term Safety and Efficacy of Lenabasum, a Cannabinoid Receptor Type 2 Agonist, in Patients with Dermatomyositis with Refractory Skin Disease: Follow-Up Data from a 3-Year Open-Label Extension Study.
JID Innov2025https://conductscience.org/library/papers/39403556PubMed
39343752Updates in Dermatomyositis: Newer Treatment Options and Outcome Measures From Dermatologic Perspectives.Ann Dermatol2024https://conductscience.org/library/papers/39343752PubMed
37378109Green Smoke, Red Flag: Cannabis and the Risk of Orbitopathy and Dermopathy in Thyrotoxicosis.Cureus2023https://conductscience.org/library/papers/37378109PubMed
36816569Cannabidiol's neuroprotective properties and potential treatment of traumatic brain injuries.Front Neurol2023https://conductscience.org/library/papers/36816569PubMed
36552866Cannabinoid Compounds as a Pharmacotherapeutic Option for the Treatment of Non-Cancer Skin Diseases.Cells2022https://conductscience.org/library/papers/36552866PubMed
35490744Safety and Efficacy of Lenabasum, a Cannabinoid Receptor Type 2 Agonist, in Patients with Dermatomyositis with Refractory Skin Disease: A Randomized Clinical Trial.J Invest Dermatol2022https://conductscience.org/library/papers/35490744PubMed
35280763COL8A1 Promotes NSCLC Progression Through IFIT1/IFIT3-Mediated EGFR Activation.Front Oncol2022https://conductscience.org/library/papers/35280763PubMed
35199092Cannabinoids for the Treatment of Dermatologic Conditions.JID Innov2022https://conductscience.org/library/papers/35199092PubMed
34983619Cannabinoid type 2 receptor (CB2R) distribution in dermatomyositis skin and peripheral blood mononuclear cells (PBMCs) and in vivo effects of LenabasumTM.Arthritis Res Ther2022https://conductscience.org/library/papers/34983619PubMed
34938263TNFα in MS and Its Animal Models: Implications for Chronic Pain in the Disease.Front Neurol2021https://conductscience.org/library/papers/34938263PubMed
34531934The Effect of Medical Cannabis on Pain Level and Quality of Sleep among Rheumatology Clinic Outpatients.Pain Res Manag2021https://conductscience.org/library/papers/34531934PubMed
34072930Cannabinoids and Inflammations of the Gut-Lung-Skin Barrier.J Pers Med2021https://conductscience.org/library/papers/34072930PubMed
33842662Pruritus in autoimmune connective tissue diseases.Ann Transl Med2021https://conductscience.org/library/papers/33842662PubMed
32637881Thymoquinone reduces ischemia and reperfusion-induced intestinal injury in rats, through anti-oxidative and anti-inflammatory effects.Turk J Surg2020https://conductscience.org/library/papers/32637881PubMed
32060787Mechanisms of Cannabinoids and Potential Applicability to Skin Diseases.Clin Drug Investig2020https://conductscience.org/library/papers/32060787PubMed
32033005Cannabinoids in the Pathophysiology of Skin Inflammation.Molecules2020https://conductscience.org/library/papers/32033005PubMed
31473845Recent Advances in Pharmacological Treatments of Adult Dermatomyositis.Curr Rheumatol Rep2019https://conductscience.org/library/papers/31473845PubMed

See all 22 cited byDownload CSV of cited by

Genes5

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
IFNA13439PubTator's text mininghttps://conductscience.org/library/genes/3439NCBI Gene
IFNB13456PubTator's text mininghttps://conductscience.org/library/genes/3456NCBI Gene
IL1B3553PubTator's text mininghttps://conductscience.org/library/genes/3553NCBI Gene
IL63569PubTator's text mininghttps://conductscience.org/library/genes/3569NCBI Gene
TNF7124PubTator's text mininghttps://conductscience.org/library/genes/7124NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/28652111

GET https://conductscience.org/api/papers/v1/28652111/cited_by?page=2